Publications by authors named "D Benitez-Ribas"
Article Synopsis
- The study investigates how the diversity of chimeric antigen receptor (CAR)-T cells affects clinical outcomes in treating B cell acute lymphoblastic leukemia (B-ALL).
- Researchers analyzed clonal dynamics and gene expression using single-cell techniques in patients receiving CD19CAR-T cells, revealing notable differences in how these T cells behave during treatment.
- Key findings include a higher CD4:CD8 ratio in successful patients' T cells at infusion and an expansion of cytotoxic T cells linked to better treatment responses across different patient cohorts.
Article Synopsis
- CAR T-cell therapies have improved the detection of M-protein in patients with relapsed/refractory multiple myeloma (RRMM), even when traditional methods fail.
- Quantitative immunoprecipitation mass spectrometry (QIP-MS) provides highly sensitive measurements of serum M-protein and can identify interferences from monoclonal antibody therapies.
- QIP-MS showed a high level of agreement with serum immunofixation, but less so with bone marrow-based flow cytometry, and it appears to be a valuable non-invasive tool for monitoring treatment responses in multiple myeloma patients.
Varnimcabtagene autoleucel (var-cel) is an academic anti-CD19 chimeric antigen receptor (CAR) product used for the treatment of non-Hodgkin lymphoma (NHL) in the CART19-BE-01 trial. Here we report updated outcomes of patients with NHL treated with var-cel. B-cell recovery was compared with patients with acute lymphoblastic leukaemia (ALL).
View Article and Find Full Text PDFAdoptive T cell therapy has successfully been implemented for the treatment of cancer. Nevertheless, ex vivo expansion of T cells by artificial antigen-presenting cells (aAPCs) remains cumbersome and can compromise T cell functionality, thereby limiting their therapeutic potential. We propose a radically different approach aimed at direct expansion of T cells in vivo, thereby omitting the need for large-scale ex vivo T cell production.
View Article and Find Full Text PDFArticle Synopsis
- - CAR T-cell therapy is a cutting-edge cancer treatment, but it often leads to complications, particularly neurotoxicity, which is not well understood in terms of how it affects the brain.
- - A study examined the brains of 6 patients who underwent this therapy, revealing various causes of death including serious infections and encephalitis, with only 2 showing significant neurological symptoms connected to the treatment.
- - The autopsy results showed mostly minor brain changes, suggesting that neurological issues may stem from factors other than CAR T-cell toxicity, highlighting the need for more research in this area.